Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: September 21, 2007

Kylin Therapeutics Signs Collaboration with Fort Dodge Animal Health, a Division of Wyeth

(Nanowerk News) Kylin Therapeutics, Inc., a biotechnology company, announced it has signed a collaboration with Fort Dodge Animal Health, a division of Wyeth (NYSE:WYE), to develop new RNAi therapeutics for the treatment of cancer. Under the terms of the three-year contract, Kylin will receive research funding, milestone payments and royalties.
Under this contract, Kylin will use its patented RNA nanoparticle technology called "pRNA" to explore the enormous potential of RNA interference (RNAi) and develop new RNA-based therapeutics for the treatment of cancer. In return for its participation in this effort, Fort Dodge will receive an exclusive license to the pRNA/RNAi therapeutic compounds for the treatment of cancers in companion animals. Kylin will retain rights to the therapies for human use.
"We are delighted to welcome Fort Dodge/Wyeth as Kylin's partner. Our business models are complementary, and the results of this effort will provide valuable data and intellectual property that will mutually serve our core businesses," said J. Eric Davis, J.D., president and CEO of Kylin Therapeutics.
The pRNA technology was developed by Peixuan Guo at Purdue University.
About Kylin Therapeutics
Kylin (http://www.kylintherapeutics.com), which is based at the Purdue Research Park, is a leading biotechnology company focused on delivery and development of RNAi based therapeutics. The company employs its revolutionary RNA nanotechnology platform called "pRNA" to develop the potential of RNA interference (RNAi) to treat many common diseases. Kylin's technology platform has the potential to meet the growing market for treating cancer, HIV and other diseases with RNA-based therapeutics.
About Fort Dodge/Wyeth
Fort Dodge Animal Health is a leading manufacturer and distributor of animal health products for the livestock, companion animal, equine, swine and poultry industries in North America and international markets. Key products include CYDECTIN® Pour-On, QUEST® Gel, the Duramune and Fel-O-Vax® vaccine lines, and West-Nile Innovator® equine vaccines. Fort Dodge is headquartered in Overland Park, Kan.
Source: Kylin Therapeutics, Inc.